Dynavax to Present at Upcoming Investor Conferences: A Look into the Company's Growth and Pipeline

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has announced its participation in two upcoming investor conferences. The company will present at the TD Cowen 45th Annual Healthcare Conference on March 4, 2025, and the Barclays 27th Annual Global Healthcare Conference on March 11, 2025. These conferences provide an opportunity for Dynavax to update investors on its progress, discuss its pipeline, and engage with potential partners and collaborators.

Dynavax's participation in these conferences reflects the company's commitment to transparency, communication, and building relationships with the investment community. By presenting at these events, Dynavax can showcase its innovative vaccines and technologies, such as HEPLISAV-B and its CpG 1018 adjuvant, to a broad audience of investors, analysts, and industry experts.

Investors can expect to hear about Dynavax's financial performance, including its record HEPLISAV-B product revenue and its expectations for net product revenue in 2025. They can also expect updates on the company's pipeline programs, such as the top-line results from the shingles vaccine Phase 1/2 program expected in Q3 2025 and the initiation of the Phase 2 trial for the plague vaccine in Q3 2025. Additionally, investors may hear about the completion of the $200 million share repurchase program in 2025.

Dynavax's participation in these conferences provides an opportunity to engage with investors and address market concerns or questions. By presenting its latest developments, financial performance, and strategic plans, Dynavax can enhance its reputation, build investor confidence, and attract new investment opportunities.